Results 71 to 80 of about 3,302 (197)

Positive and Negative Cardiovascular Effects of JAK Inhibitors in Inflammation

ACR Open Rheumatology, Volume 8, Issue 6, June 2026.
Chronic inflammation, characteristic of many autoimmune diseases, such as rheumatoid arthritis (RA), or myeloproliferative neoplasms (MPNs), is an independent driver of accelerated cardiovascular (CV) risk, primarily through proinflammatory cytokines that induce atherosclerosis and endothelial dysfunction.
Aliki Zavoriti, Pierre Miossec
wiley   +1 more source

Use Patterns of Novel Janus Kinase Inhibitors After the First Safety Alerts: A Nationwide Register‐Based Time Series Analysis

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Purpose Janus kinase inhibitors (JAKi) are medicines used to treat inflammatory rheumatic musculoskeletal diseases (IRMDs) and inflammatory bowel diseases (IBDs). In Europe, JAKis received marketing authorisation in 2017 for rheumatoid arthritis.
Jarno Rutanen, Pekka Heino, Kati Sarnola, Terhi Kurko   +3 more
wiley   +1 more source

In which patients with ulcerative colitis would filgotinib be effective?

Intestinal Research
Article: Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study (Intest Res 2025;23:65-75)
Jihye Park
semanticscholar   +1 more source

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis

Drugs in Context, 2019
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by joint involvement, extra-articular manifestations, comorbidities, and increased mortality.
Martina Biggioggero, Andrea Becciolini, Chiara Crotti, Elena Agape, Ennio Giulio Favalli   +4 more
doaj   +1 more source

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Rheumatology &Autoimmunity, Volume 6, Issue 2, Page 94-104, June 2026.
Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi Tsuchimoto, Koji Kinoshita, Itaru Matsumura   +4 more
wiley   +1 more source

Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis—A Prospective, Real‐World Study From the Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)

United European Gastroenterology Journal, Volume 14, Issue 5, June 2026.
ABSTRACT Background Mirikizumab (MIRI), an IgG4 monoclonal antibody targeting IL‐23 p19, was recently licensed for ulcerative colitis (UC). Most available data come from the pivotal trials, but real‐life data are scant. We aimed to evaluate the effectiveness and safety of MIRI in a real‐world setting.
Giuseppe Costantino, Anna Viola, Andrea Iuculano, Fabio Salvatore Macaluso, Raffaele Li Voti, Maria Cappello, Chiara Antoci, Concetta Ferracane, Morena Sciuto, Domenico Catarella, Stefanie Parisi, Filippo Mocciaro, Barbara Scrivo, Maria Emanuela Distefano, Roberto Vassallo, Maria Giovanna Minissale, Giuseppe Scalisi, Serena Garufi, Sofia Rao, Stefano Muscarella, Vincenza Tortorella, Emiliano Giangreco, Marco Muscianisi, Ambrogio Orlando, Walter Fries   +24 more
wiley   +1 more source

Unveiling the Potential of JAK Inhibitors in Inflammatory Bowel Disease

Biologics
Background: Janus kinase (JAK) inhibitors represent a novel class of oral therapies showing efficacy in treating ulcerative colitis (UC) and Crohn’s disease (CD), challenging conventional treatment paradigms.
Shahed Kamal, Sheng Wei Lo, Samantha McCall, Beverly Rodrigues, Andrew H. Tsoi, Jonathan P. Segal   +5 more
doaj   +1 more source

Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody [PDF]

Intestinal Research
Background/Aims Tofacitinib (TFB), filgotinib (FIL), and upadacitinib (UPA) are Janus kinase (JAK) inhibitors approved for moderate-to-severe ulcerative colitis (UC).
Maiko Ikenouchi, Hirokazu Fukui, Soichi Yagi, Akira Nogami, Koji Kaku, Toshiyuki Sato, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Tetsuya Takagawa, Toshihiko Tomita, Taku Kobayashi, Shinichiro Shinzaki   +12 more
doaj   +1 more source

Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence

Pharmaceuticals
Ulcerative colitis (UC) is an inflammatory bowel disease in which one-quarter of patients are at risk of developing a severe form of the disease known as acute severe UC (ASUC).
Raffaele Pellegrino, Giuseppe Imperio, Ilaria De Costanzo, Michele Izzo, Fabio Landa, Assunta Tambaro, Antonietta Gerarda Gravina, Alessandro Federico   +7 more
doaj   +1 more source

Clear Cell Renal Carcinoma in an Ulcerative Colitis Patient Under Short-Term Immunosuppressive Therapy: A Case Report

Clinics and Practice
Background/Objectives: Renal cell cancer is a rare occurrence in patients with ulcerative colitis (UC), with no clearly demonstrated association between UC and an increased risk of renal malignancies.
Raffaele Pellegrino, Giuseppe Imperio, Michele Izzo, Ilaria De Costanzo, Fabio Landa, Paola Ciamarra, Marco Niosi, Antonietta Gerarda Gravina, Alessandro Federico   +8 more
doaj   +1 more source